The incorporation of GLP-1 receptor agonists into personalized treatment algorithms shows potential for improving outcomes and boosting the overall quality of life for persons with T2DM as the area of diabetes management progresses. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.